Overview

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Status:
Completed

Trial end date:
2019-08-16

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab